Corporate Banner
Satellite Banner
Next Gen Sequencing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Illumina Announces Oncology CDx Partnership with AstraZeneca, Janssen and Sanofi

Published: Thursday, August 21, 2014
Last Updated: Thursday, August 21, 2014
Bookmark and Share
Illumina, forms collaborative partnerships with leading pharmaceutical companies to develop a universal next-generation sequencing (NGS)-based oncology test system.

The system will be used for clinical trials of targeted cancer therapies with a goal of developing and commercializing a multi-gene panel for therapeutic selection, resulting in a more comprehensive tool for precision medicine. Initial strategic partners include AstraZeneca, Janssen Biotech, Inc., and Sanofi. 

Illumina is working with the strategic partners to develop assays that detect and measure multiple variants simultaneously to support partners' clinical trials, with the objectives of securing regulatory agency approvals and test commercialization. In parallel, Illumina is working with key thought leaders to set standards for NGS-based assays in routine clinical oncology practice, as well as to define regulatory frameworks to enable this new testing paradigm. Together, Illumina and its strategic partners aim to transition from single-analyte companion diagnostics to panel-based assays that select for "companion therapeutics." 

"The transition to patient-centered companion therapeutics marks a new era for oncology, and we are pleased to see pharmaceutical companies working with Illumina on a universal platform to bring life-saving treatments through their development pipelines," said Ellen V. Sigal, Ph.D., Chair and Founder of Friends of Cancer Research. "This is the type of collaboration that will make real progress for patients." 

Ruth March, Vice President, Personalised Healthcare & Biomarkers at AstraZeneca, said, "This partnership has the potential to deliver an unprecedented amount of clinical information from a single test. Illumina's technology will inform doctors about the molecular make-up of their patients' tumors, enabling them to match medicines to the drivers of disease. Our aim is that doctors can use these tests to prescribe the right drugs to the right patients - bringing benefits to healthcare professionals, payers and patients alike." 

To date 125 known cancer driver genes have been discovered - 71 tumor suppressors and 54 oncogenes - that drive tumor growth through 12 cellular signaling pathways.1 While today the number of available targeted therapies is limited, an estimated 800 oncology drugs are in development, many of which are designed to target specific mutations. With the emergence of new targeted therapies, there is growing need for new companion diagnostic tests. 

"Building on our experience with the MiSeqDx, the only FDA-cleared NGS platform, as well as the additional regulatory expertise we gained with the acquisition of Myraqa, Illumina is developing the universal test system to support our partners' oncology drug pipelines," said Rick Klausner, M.D., Illumina's Chief Medical Officer. "These agreements represent the deep engagement between Illumina and the pharma community to create the technical, clinical, regulatory and ultimately commercial solutions for the next generation of molecular oncology. We're excited to be working together to maximize benefits to patients with cancer." 


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Burning Rock and Illumina Collaborate on Molecular Diagnostics for Oncology
Collaboration highlights the ever-increasing importance of genomics to improve healthcare in China.
Tuesday, August 25, 2015
Illumina, Warburg Pincus, and Sutter Hill Ventures Form Helix
LabCorp to be initial strategic partner in development of consumer applications.
Tuesday, August 18, 2015
Illumina to Acquire GenoLogics
Illumina has signed a definitive agreement to acquire GenoLogics, a developer of LIMS for life science organizations.
Wednesday, August 05, 2015
Illumina Names Sanjay Chikarmane as SVP and General Manager
Chikarmane will report to Illumina President, Francis deSouza.
Tuesday, July 21, 2015
Discordant NIPT Test Results May Reflect Presence of Maternal Cancer
Results published in Journal of the American Medical Association.
Tuesday, July 14, 2015
Annoroad and Illumina to Co-Develop NGS Diagnostic System
Both Companies have entered into an agreement to jointly develop advanced clinical applications for reproductive health.
Thursday, June 11, 2015
Illumina Files New Patent Infringement Suit
Company has filed a new suit against Ariosa Diagnostics, Inc. and Roche Molecular Systems, Inc.
Tuesday, May 19, 2015
The Agrigenomics Market
Exponential population growth and changing climate patterns are creating unique challenges for the agriculture industry. To continue to address global food needs, many researchers, breeders, and farms are turning to genomics, or DNA science, to optimize production.
Thursday, May 07, 2015
Illumina Files Patent Infringement Suit Against Premaitha
Patent infringement suit filed in the United Kingdom against Premaitha Health plc for infringement of NIPT patents.
Monday, March 16, 2015
Illumina Announces Strategic Collaboration with Merck Serono
Collaboration to expand companion diagnostics for oncology.
Friday, March 13, 2015
Illumina and Merck Serono Collaborate
Strategic collaboration will expand companion diagnostics for oncology.
Tuesday, March 10, 2015
Illumina Accelerator Secures $40 Million Boost Capital to Back New Graduates
Obtains commitment from viking global investors to advance genomics startups.
Friday, February 27, 2015
Illumina Q4 Revenues Up 32%
Illumina has announced its financial results for the fourth quarter and fiscal year 2014.
Wednesday, January 28, 2015
£15m Initiative Puts Scotland at Forefront of Gene-Led Healthcare
Initiative sees the Universities of Edinburgh and Glasgow partner with Illumina.
Monday, January 12, 2015
Illumina Announces AOCC to Receive Agricultural Greater Good Initiative Grant
Project designed to improve food security in Africa.
Friday, January 09, 2015
Scientific News
Genetic Overlapping in Multiple Autoimmune Diseases May Suggest Common Therapies
CHOP genomics expert leads analysis of genetic architecture, with eye on repurposing existing drugs.
Surprising Mechanism Behind Antibiotic-Resistant Bacteria Uncovered
Now, scientists at TSRI have discovered that the important human pathogen Staphylococcus aureus, develops resistance to this drug by “switching on” a previously uncharacterized set of genes.
The Changing Tides of the In Vitro Diagnostics Market
With the increasing focus in personalized medicine, diagnostics plays a crucial role in patient monitoring.
Data Mining DNA For Polycystic Ovary Syndrome Genes
A new Northwestern Medicine genome-wide association study of PCOS – the first of its kind to focus on women of European ancestry – has provided important new insights into the underlying biology of the disorder.
Viral Comparisons
ORNL team applies genomics expertise to analyze, map virus sequence database.
The Tree of Life — More Like A Bush
New species evolve whenever a lineage splits off into several. Because of this, the kinship between species is often described in terms of a ‘tree of life’, where every branch constitutes a species.
Ancient Origins of Deadly Lassa Virus Uncovered
Working as part of an international team in North America and West Africa, a researcher at The Scripps Research Institute (TSRI) has published new findings showing the ancient roots of the deadly Lassa virus, a relative of Ebola virus, and how Lassa virus has changed over time.
Furthering Data Analysis of Next-gen Sequencing to Facilitate Research
Researchers at Cincinnati Children's Hospital Medical Center have developed a user-friendly, integrated platform for analyzing the transcriptomic and epigenomic "big data.
Statistical Technique Helps Researchers Understand Tumor Makeup, Personalize Cancer Treatments
A new statistical method for analyzing next-generation sequencing (NGS) data that helps researchers study the genome of various organisms such as human tumors and could help bring about personalized cancer treatments has been unveiled.
‘Fishing Expedition’ Nets Nearly Tenfold Increase in Number of Sequenced Virus Genomes
Newly developed computational tool finds 12,500 genomes of viruses that infect microbes.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!